Summary - Funding Rounds

Founding Date

1996
Sucampo Pharmaceuticals is a subsidiary of Mallinckrodt Pharmaceuticals

Sucampo Pharmaceuticals Income Statement

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

54.8m81.5m89.6m115.5m153.2m230.1m

Revenue growth, %

29%33%50%

Cost of goods sold

3.0m12.4m16.3m36.7m76.0m

Gross profit

78.5m77.2m99.2m116.4m154.1m

Gross profit Margin, %

96%86%86%76%67%

Sales and marketing expense

8.8m18.7m21.1m14.5m2.8m2.5m

R&D expense

33.5m21.3m21.5m20.6m33.6m46.6m

General and administrative expense

41.3m30.2m25.4m31.2m35.5m43.8m

Operating expense total

83.6m70.1m68.0m72.0m72.0m100.2m

EBIT

(17.7m)8.3m9.2m27.2m44.5m53.9m

EBIT margin, %

(32%)10%10%24%29%23%

Interest expense

2.5m2.3m1.2m98.0k784.0k39.5m

Interest income

249.0k179.0k124.0k172.0k181.0k72.0k

Pre tax profit

(21.9m)7.8m10.3m27.1m43.7m14.4m

Income tax expense

(4.6m)2.9m3.9m14.0m10.3m(4.1m)

Net Income

(17.3m)4.8m6.4m13.1m33.4m18.5m

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

14.0m14.4m14.4m16.7m15.5m16.9m27.0m21.2m22.2m24.1m31.5m29.5m34.9m33.4m47.2m52.0m57.9m56.3m59.9m61.3m

Cost of goods sold

1.3m1.9m6.3m3.5m3.8m5.0m6.1m7.3m5.3m23.3m20.4m15.6m16.9m17.0m17.4m

Gross profit

15.6m25.1m14.9m18.6m20.3m26.5m23.4m27.6m28.2m23.9m31.6m42.3m39.4m42.9m43.8m

Gross profit Margin, %

92%93%70%84%84%84%79%79%84%51%61%73%70%72%72%

Sales and marketing expense

2.0m2.2m4.1m6.1m4.3m5.4m4.6m6.0m3.6m4.0m3.8m640.0k592.0k385.0k775.0k623.0k696.0k516.0k1.4m2.5m

R&D expense

7.9m8.7m3.4m5.2m5.6m5.6m4.4m4.5m5.1m4.3m5.3m6.8m7.1m8.4m14.7m10.9m10.0m10.3m19.1m10.1m

General and administrative expense

11.7m7.9m7.3m8.0m7.3m7.2m6.0m5.4m7.3m8.2m8.1m6.3m8.3m7.8m8.9m12.4m11.1m17.7m11.6m10.0m

Operating expense total

21.6m18.9m14.8m33.1m28.3m18.2m14.9m15.9m16.0m16.5m22.8m13.7m16.0m16.5m24.4m24.0m29.0m28.5m218.7m22.6m

EBIT

(7.6m)(4.5m)(322.0k)(2.7m)(1.7m)(2.6m)10.2m(1.0m)2.6m3.8m3.6m9.7m11.6m11.7m(503.0k)7.6m13.3m10.9m(175.8m)21.2m

EBIT margin, %

(54%)(31%)(2%)(16%)(11%)(15%)38%(5%)12%16%12%33%33%35%(1%)15%23%19%(294%)35%

Interest expense

614.0k619.0k592.0k592.0k596.0k495.0k493.0k490.0k666.0k422.0k161.0k439.0k1.9m94.0k6.6m8.5m2.2m2.7m3.4m3.6m

Interest income

55.0k35.0k20.0k30.0k68.0k19.0k23.0k20.0k57.0k23.0k26.0k40.0k53.0k62.0k25.0k10.0k31.0k28.0k10.0k

Pre tax profit

(11.3m)(3.9m)380.0k(3.8m)(2.2m)(2.0m)10.4m(1.5m)1.9m3.4m3.8m9.2m13.4m11.6m(7.1m)(883.0k)15.5m8.2m(179.2m)17.6m

Income tax expense

(2.3m)196.0k2.3m(3.0m)3.8m1.1m4.3m(2.8m)1.3m1.8m2.3m2.8m3.9m4.3m(3.0m)(51.0k)7.4m3.6m1.9m7.2m

Net Income

(9.0m)(4.1m)(1.9m)(819.0k)(5.9m)(3.1m)6.1m1.3m675.0k1.6m1.5m6.4m9.6m7.2m(4.1m)(832.0k)8.1m4.6m(181.2m)10.4m

Sucampo Pharmaceuticals Balance Sheet

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Cash

50.7m52.0m44.1m71.6m108.3m198.3m

Accounts Receivable

4.6m1.4m5.4m5.3m22.8m43.0m

Prepaid Expenses

1.2m1.9m4.0m3.4m8.9m

Inventories

209.0k33.1m23.5m

Current Assets

114.9m92.9m113.4m122.3m251.4m307.2m

PP&E

1.7m1.5m1.2m763.0k6.4m6.2m

Goodwill

60.9m73.0m

Total Assets

157.6m127.8m137.0m141.6m457.2m520.9m

Accounts Payable

7.0m5.5m7.6m4.1m11.2m9.2m

Short-term debt

20.4m19.1m26.9m8.2m39.1m

Current Liabilities

47.1m40.1m42.6m33.8m88.1m32.4m

Long-term debt

39.2m33.7m25.8m17.6m213.3m

Total Debt

59.6m52.9m25.8m

Total Liabilities

119.0m84.8m78.8m59.3m370.7m353.8m

Preferred Stock

Additional Paid-in Capital

60.0m62.5m72.1m83.6m99.2m120.3m

Retained Earnings

(38.9m)(34.1m)(27.7m)(13.7m)19.6m38.1m

Total Equity

38.6m43.0m58.1m82.3m86.4m167.1m

Financial Leverage

4.1 x3 x2.4 x1.7 x5.3 x3.1 x

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

52.3m55.3m55.5m61.7m57.2m48.6m47.3m39.9m56.1m53.5m56.1m59.6m71.3m91.5m130.1m128.0m128.5m243.5m84.7m75.0m

Accounts Receivable

732.0k1.1m1.1m606.0k1.2m1.8m3.6m2.7m4.4m4.8m8.5m8.2m8.2m6.7m16.1m18.2m20.7m20.5m19.8m33.1m

Prepaid Expenses

1.6m1.7m1.8m1.6m2.6m2.7m3.9m3.8m3.6m3.4m3.6m2.9m2.8m3.7m14.1m24.3m18.1m16.7m16.7m34.7m

Inventories

4.0m4.9m261.0k455.0k423.0k133.0k328.0k308.0k296.0k24.4m21.6m24.2m23.0m23.1m24.2m

Current Assets

129.9m122.6m109.4m105.1m100.4m101.6m108.1m105.7m122.6m119.3m124.1m120.9m136.7m161.4m228.1m237.7m237.5m322.4m165.1m190.1m

PP&E

1.9m1.8m1.6m1.7m1.6m1.5m1.4m1.3m1.1m979.0k882.0k634.0k526.0k2.3m6.9m6.3m6.6m6.2m5.9m5.7m

Goodwill

65.8m71.8m73.0m73.0m73.0m73.0m

Total Assets

145.6m142.8m150.1m124.9m121.1m133.4m135.3m129.7m144.2m142.2m144.6m149.8m160.3m173.8m448.2m469.7m459.6m529.2m365.1m388.1m

Accounts Payable

4.2m6.3m5.6m5.3m3.5m9.3m5.7m2.9m6.0m5.6m5.9m1.4m3.9m4.9m5.1m6.2m7.9m8.0m11.2m6.2m

Short-term debt

19.5m20.5m19.7m20.1m20.3m28.7m27.9m28.1m27.3m27.8m26.3m8.2m8.4m8.4m27.8m21.7m21.7m291.0m291.5m291.9m

Current Liabilities

46.7m49.6m41.9m38.5m36.4m49.3m47.0m39.7m43.6m42.5m43.9m30.7m32.8m33.5m62.4m55.6m66.8m34.8m32.1m37.2m

Long-term debt

45.6m46.2m39.8m40.3m40.9m33.7m29.8m29.8m25.8m21.7m21.7m17.6m13.3m13.3m207.9m202.4m197.0m

Total Debt

65.1m66.7m59.5m60.4m61.2m62.5m57.7m57.9m53.2m49.5m48.1m25.8m21.7m21.7m235.7m224.1m218.7m291.0m291.5m291.9m

Total Liabilities

103.8m106.8m114.2m89.3m91.8m93.3m87.0m79.9m78.8m72.9m73.0m55.8m53.5m56.0m347.4m346.0m314.8m354.9m338.7m348.5m

Common Stock

420.0k423.0k423.0k

Preferred Stock

Additional Paid-in Capital

59.1m59.5m60.8m61.3m61.7m62.9m65.4m65.8m78.8m80.4m80.9m88.8m92.2m95.7m102.1m105.1m113.4m124.0m127.2m130.1m

Retained Earnings

(37.6m)(41.6m)(40.9m)(41.7m)(47.6m)(37.2m)(31.1m)(29.8m)(27.0m)(24.5m)(23.0m)(7.3m)2.3m9.5m15.6m14.8m22.8m41.7m(151.7m)(141.4m)

Total Equity

41.8m36.0m35.9m35.6m29.4m40.0m48.4m49.8m65.4m69.4m71.7m94.0m106.7m117.8m100.8m123.8m144.8m174.3m26.3m39.6m

Financial Leverage

3.5 x4 x4.2 x3.5 x4.1 x3.3 x2.8 x2.6 x2.2 x2.1 x2 x1.6 x1.5 x1.5 x4.4 x3.8 x3.2 x3 x13.9 x9.8 x

Sucampo Pharmaceuticals Cash Flow

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(17.3m)4.8m6.4m13.1m33.4m18.5m

Depreciation and Amortization

1.3m1.5m1.5m1.1m10.6m45.7m

Accounts Receivable

(3.9m)3.3m(4.0m)67.0k(8.5m)(18.8m)

Inventories

(127.0k)87.0k(163.0k)206.0k(1.4m)(1.2m)

Accounts Payable

2.9m(1.5m)2.2m(3.4m)(1.7m)(2.8m)

Cash From Operating Activities

(20.0m)12.0m(5.4m)30.9m18.6m8.3m

Purchases of PP&E

(284.0k)(439.0k)(168.0k)(66.0k)(3.6m)(1.2m)

Capital Expenditures

(1.9m)

Cash From Investing Activities

27.9m(589.0k)(13.9m)13.0m(131.2m)(1.8m)

Short-term Borrowings

(7.5m)(7.5m)(24.9m)(8.2m)(269.9m)

Cash From Financing Activities

(8.1m)(8.4m)10.6m(15.4m)149.3m70.5m

Net Change in Cash

1.4m1.4m(7.9m)27.5m36.7m90.0m

Interest Paid

171.0k156.0k129.0k6.0m20.0m

Income Taxes Paid

1.5m3.7m4.9m9.2m17.6m13.6m

Free Cash Flow

16.7m

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Net Income

(15.9m)(20.0m)(1.9m)(2.7m)(8.7m)(3.1m)3.0m4.3m675.0k2.4m3.8m6.4m16.0m23.2m(4.1m)(4.9m)3.2m4.6m(176.5m)(166.2m)

Depreciation and Amortization

650.0k1.0m350.0k731.0k1.1m381.0k753.0k1.1m361.0k721.0k984.0k83.0k215.0k433.0k15.6m30.1m37.9m7.4m14.9m22.4m

Accounts Receivable

(2.0k)(408.0k)3.5m4.0m3.4m(481.0k)(2.3m)(1.3m)965.0k652.0k(3.0m)(2.7m)(2.8m)(911.0k)8.4m10.8m3.5m22.5m23.4m10.2m

Inventories

2.0k87.0k87.0k(3.9m)(4.8m)(218.0k)(245.0k)(211.0k)74.0k(328.0k)(308.0k)(296.0k)1.8m309.0k(2.0m)490.0k370.0k(708.0k)

Accounts Payable

(50.0k)2.1m(1.3m)(1.6m)(3.5m)3.9m294.0k(2.4m)(1.6m)(2.0m)(1.7m)(2.7m)(221.0k)785.0k(6.3m)(5.8m)(4.1m)(1.2m)458.0k(4.5m)

Cash From Operating Activities

(14.4m)(17.1m)4.8m768.0k(5.2m)(5.6m)(5.9m)(8.2m)3.6m4.1m7.5m4.6m15.1m24.2m23.6m25.8m30.3m45.3m56.2m50.9m

Purchases of PP&E

(180.0k)(284.0k)(40.0k)(265.0k)(306.0k)(120.0k)(140.0k)(153.0k)(41.0k)(49.0k)(62.0k)(12.0k)(47.0k)(2.0m)(735.0k)(823.0k)(1.2m)(350.0k)(354.0k)(403.0k)

Cash From Investing Activities

13.7m21.4m2.3m12.0m14.1m(7.9m)(7.5m)(12.3m)1.9m1.6m1.2m(20.7m)(16.0m)(6.8m)(3.3m)(2.9m)(1.8m)(350.0k)(170.0m)(175.1m)

Short-term Borrowings

(3.9m)(3.9m)(4.1m)(4.1m)(17.6m)(30.1m)(36.3m)

Cash From Financing Activities

104.0k(43.0k)51.0k78.0k(474.0k)10.3m8.4m8.4m6.5m3.5m3.5m4.2m700.0k2.4m1.1m(10.2m)(16.4m)308.0k319.0k926.0k

Net Change in Cash

3.0m6.0m4.8m11.0m6.6m(3.4m)(4.7m)(12.1m)12.0m9.4m12.0m(12.0m)(279.0k)19.9m21.8m19.7m20.2m45.2m(113.6m)(123.3m)

Income Taxes Paid

(5.0k)(1.2m)(4.1m)

Sucampo Pharmaceuticals Ratios

USDQ2, 2011

Financial Leverage

3.5 x

Sucampo Pharmaceuticals Employee Rating

3.214 votes
Culture & Values
3.1
Work/Life Balance
4.2
Senior Management
3.4
Salary & Benefits
2.9
Career Opportunities
2.9
Source